Imunon, Inc. IMNN
0.59 USD -0.02 (-3.46%)
As ofNov 18, 2026, 2:06 PM EST
0.5741 Day range 0.6432
0.50 52-week range 4.35
- YTD
- -84.49%
- 1 year
- -85.55%
Benzinga news
benzinga.com Imunon Q3 2026 Earnings Call Transcript Imunon (NASDAQ:IMNN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Imunon Q3 EPS $(0.64) Misses $(0.55) Estimate Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.55) by 16.36 percent. This is a 44.83 percent increase over losses of $(1.16)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…benzinga.com IMUNON Sells ThermoDox Rights To VoxelDox; IMUNON Receive Equity Ownership Stake In VoxelDox With Payments Of Up To $16.5M Contingent On Meeting Development Milestones And Royalties Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma TrialSale Reinforces IMUNON's…
